Monopar Therapeutics(us:MNPR)

    25.82

    +8.53%

    Updated on 2024-12-22

    Open:30.40
    Close:25.82
    High:30.40
    Low:23.67
    Pre Close:23.79
    Volume:139076.00
    Amount:3.58M
    Turnover:2.64%
    Shares:5.28M
    MarketCap:136.27M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-3017836320.48%156
    2024-03-31193953282.26%635
    2023-12-31172713121.82%446
    2023-09-30143013102.12%606
    2023-06-30131924401.38%226
    2023-03-31122209201.67%323
    2022-12-31111880331.45%135
    2022-09-30141991261.55%235
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Millennium Management Llc1923811.10%163040555.67%
    2024-03-31Vanguard Group Inc451670.26%0
    2024-03-31Geode Capital Management, Llc411990.24%0
    2024-03-31Hrt Financial Lp321130.18%32113
    2024-03-31Gerber, Llc280050.16%0
    2024-03-31Virtu Financial Llc238270.14%-3343-12.30%
    2024-03-31Rappaport Reiches Capital Management, Llc106950.06%0
    2024-03-31Tower Research Capital Llc (Trc)78560.04%4238117.14%
    2024-03-31Fmr Llc55000.03%5500
    2024-03-31Newedge Advisors, Llc30000.02%3000

    About

    Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
    Address:1000 Skokie Boulevard,Suite 350

    Market Movers